周二,Wolfe Research将argenx SE (NASDAQ: ARGX)的股票评级从Peerperform上调至Outperform,目标价为697.00美元。该公司预计,在肌炎和PFS项目的推动下,argenx到2025年将呈现积极发展态势,并有望在重症肌无力(MG)市场保持主导地位,尤其是在竞争对手Biohaven和Immunovant发布最新消息后。 Wolfe Research ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

argenx SE (NASDAQ:ARGX – Free Report) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

(NASDAQ:ARGX – Get Free Report) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” ...

Argenx (NASDAQ:ARGX) announces that it has updated the number of ADSs in its U.S. public offering to 3.5M ADSs yielding $150M. Each of the ADSs represents one ordinary... Investing.com – U.S ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...